Recently
T he NOD mouse represents an animal model of human type I diabetes (1) . Inflammation of the pancreatic islets of Langerhans in NOD mice starts before 3 wk of age with infiltration initially by dendritic cells (DC) 3 and macrophages, which is soon followed by the recruitment of lymphocytes. Despite extensive infiltration of the pancreatic islets, called insulitis, the disease remains clinically silent for many weeks (2) . In our colony, NOD mice only start to become hyperglycemic beyond 15 wk of age. The considerable lag between the beginning of insulitis and the onset of overt diabetes suggests that regulatory mechanisms that delay disease progression are present in prediabetic NOD mice. However, diabetes can be rapidly transferred into immuneincompetent NOD recipients with islet-infiltrating cells (IIC) isolated from inflamed pancreata of prediabetic NOD mice (3) . Both CD4 ϩ and CD8 ϩ T cells are necessary for efficient transfer of disease (4) . Splenocytes from prediabetic NOD mice transfer diabetes less rapidly than IIC and, in cotransfer with IIC, delay diabetes transfer (3, 4) . These data suggest that peripheral (as opposed to intraislet) regulation is critical for maintaining NOD insulitis in a nondestructive state. Several lines of evidence suggest that CD4 ϩ splenocytes contain the regulatory function in prediabetic NOD mice (5) . Both of the cell surface markers, CD45RB and CD62L, have been successfully used to define these regulatory CD4 ϩ T cells as subpopulations expressing CD4 ϩ CD45RB low or CD4 ϩ CD62L ϩ (6 -8) .
More recently, it was demonstrated that CD25-depleted splenocytes from prediabetic NOD mice more rapidly transferred diabetes into immune-incompetent NOD mice than did total splenocytes, suggesting that CD4 ϩ CD25 ϩ T cells play a role in immune regulation in the NOD mouse (9) . Based on these studies, some recent reviews have defined the regulatory T cell population in prediabetic NOD mice as CD4 ϩ CD25 ϩ CD62L ϩ (5, 10). However, experimental evidence for this functional phenotype has been lacking to date. CD4 ϩ CD25 ϩ T cells have been shown to be potent regulatory cells in a number of mouse models as well as in rats and humans (9, (11) (12) (13) (14) (15) . The mechanism of action by which CD4 ϩ CD25 ϩ T cells prevent the development of autoimmune disease is not completely understood. CD4 ϩ CD25 ϩ T cells, activated in vitro, suppress the proliferation of responder CD4 ϩ CD25 Ϫ T cells in a cell contact-dependent manner (16) . Their effect in vivo appears (in some, but not all, systems) to depend on IL-10 and/or TGF-␤ expression (17) . Very little is known about the trafficking behavior of CD4 ϩ CD25 ϩ T cells or the site where they exert their regulatory activity in vivo. CD4 ϩ CD25 ϩ T cells can be easily found in secondary lymphoid organs. CD4 ϩ CD25 ϩ splenocytes express high levels of CCR5 and are attracted by activated APCs that express macrophage inflammatory protein-1␤ (ligand for CCR5). This may be essential for maintaining normal humoral immune responses in the secondary lymphoid tissues (18) . At the same time, CD4 ϩ
CD25
ϩ T cells from human peripheral blood selectively express CCR8 and CCR4 and show a strong chemotactic response to ligands for CCR4, monocyte-derived chemokine (MDC), and thymus-and activationregulated chemokine (TARC). These chemokines are produced at high levels by activated APC and attract activated T cells, suggesting that CD4 ϩ
ϩ T cells may be attracted to inflamed tissues to regulate or prevent autoimmune disease (19) .
In this manuscript we demonstrate that CD4 ϩ CD25 ϩ CD62L ϩ , and not CD4 ϩ CD25 ϩ CD62L Ϫ , splenocytes inhibit diabetes transfer into immune-compromised NOD mice, whereas both subsets are equally effective in suppression assays in vitro. We address whether differential trafficking of these two subsets may explain these seemingly contradictory results.
Materials and Methods

Mice
Female NOD mice were obtained from Taconic Farms (Germantown, NY). Female NOD.SCID mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and were used as recipients between 4 -6 wk of age. All animals were maintained under specific pathogen-free conditions at the Department of Comparative Medicine, Stanford University School of Medicine (Stanford, CA).
Antibodies
Purified anti-CD3 (145-2C11) and anti-CD28 (37.51), FITC-labeled anti-CD4 (GK1.5), anti-CD62L (MEL-14), PE-labeled anti-CD25 (PC61), biotinylated anti-CD25 (7D4), and CyChrome-labeled anti-CD4 (RM4-5) were purchased from BD PharMingen (San Diego, CA). PE-conjugated streptavidin was purchased from Caltag Laboratories (Burlingame, CA).
Lymphocyte preparation
Single cells containing IIC were prepared from the pancreata of 11-wk-old NOD mice using a procedure previously described (20 
FACS analysis and FACS sorting
Cell preparation was performed in PBS (Life Technologies, Gaithersburg, MD) plus 5% heat-inactivated FBS (HyClone, Logan, UT). Cells were sorted aseptically on a FACStar cell sorter (BD Biosciences, Mountain View, CA) in the Shared FACS Facility, Center for Molecular and Genetic Medicine, Stanford University. The data were analyzed using the Herzenberg desk facility (Stanford University), FloJo 2.7.8 (TreeStar, San Carlos, CA).
Cell transfer procedure
Cells were resuspended in PBS and were injected i.p. at the numbers indicated. NOD.SCID recipients were checked for glucosurea using Glucostix (Roche, Indianapolis, IN) twice a week. If glucosurea was observed, blood glucose was measured with a One Touch Basic glucometer (Johnson & Johnson, Milpitas, CA). Mice with glucosurea and blood glucose 250 mg/dl were considered diabetic. Glucosurea always coincided with high blood glucose levels.
In vitro proliferation assays
RPMI-C, i.e., RPMI 1640 (BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated FBS, 10 mM HEPES, 1% nonessential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin plus 100 g/ml streptomycin, 2 mM L-glutamine (all obtained from Life Technologies), and 50 M 2-ME (Sigma, St. Louis, MO), was used for in vitro cultures. Cells were incubated with equal number of anti-CD3-and anti-CD28-coated beads in RPMI-C in 96-well U-bottom plates (BD Biosciences). Beads were coated as described previously (21) using 2.5 g/ml anti-CD3 and 2.5 g/ml anti-CD28 mAbs. Cells were pulsed with 1 Ci 
Analysis of chemokine receptor mRNA by RNase protection assay
Sorted cells were washed in PBS, pelleted, and frozen. RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA). Probes were labeled with [␣- 32 -P]UTP and hybridized with the isolated RNA. Two custom-designed probe sets (BD PharMingen) were used. One set detects CCR1, CXCR4, CCR5, BLR-1, CCR8, CCR6, L32, and GAPDH. The other set detects CXCR2, CCR3, CCR4, CCR2, CCR7, CXCR3, L32, and GAPDH. After digestion of ssRNA, the protected fragments were separated by PAGE. Controls included the probe set hybridized to tRNA only and to tRNA plus a pool of synthetic sense RNAs complementary to the probe set. For quantification, autoradiographs were scanned on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA), and band density was assessed with ImageQuant image software (Molecular Dynamics, Sunnyvale, CA). The arbitrary units of expression levels for the chemokine receptors are the values obtained from the densitometer and normalized against GAPDH.
Chemotaxis assays
Sorted cells were allowed to incubate in RPMI-C for 1 h at 37°C. Migration assays were performed in Costar 24-well plate tissue culture inserts with 5-m pore size polycarbonate filters (Corning, Corning, NY). All recombinant mouse chemokines were purchased from R&D Systems (Minneapolis, MN) and were used at the following final concentrations: ELC (macrophage-inflammatory protein-3␤), 100 nM; secondary lymphoid tissue chemokine (SLC), 100 nM; monokine induced by IFN-␥, 100 nM; IFN-␥-inducible protein 10, 25 nM; MDC 100 nM; and TARC, 100 nM. Six hundred microliters of the diluted chemokine solution was placed in the lower well, and 100 l medium containing cells (1 ϫ 10 5 ) was placed in the upper chamber. Migration was conducted in equilibrated RPMI-C at 37°C with 6% CO 2 for 90 min. After removal of the Transwell insert, 400 l of the medium in the lower well containing the migrated cells was mixed with 5 ϫ 10 4 PE-streptavidin (Caltag Laboratories)-labeled latex beads (Interfacial Dynamics, Portland, OR) and analyzed by FACS. The percentage of cells that had migrated through the filter was determined by counting the proportion of cells vs PE-positive beads, taking into account the volumes. Background/nonspecific migration was assessed by migration to plain medium.
Statistical analysis
For comparison of disease onset times, the Mann-Whitney U test was used.
Results and Discussion
CD4 ϩ CD25 ϩ splenocytes
delay diabetes onset, induced by isletinfiltrating lymphocytes, in coadoptive transfer studies into immune-compromised NOD mice
Prompted by the previous observations that IIC from prediabetic NOD mice rapidly transferred diabetes into NOD.SCID recipients (3) and that total splenocytes from prediabetic NOD mice inhibited this transfer of disease (4), we attempted to identify the splenocyte subset that mediated this protective effect. We tested the effects of CD4 ϩ , CD4 ϩ CD25 ϩ , or CD4 ϩ CD25 Ϫ splenocytes on diabetes onset following cotransfer with IIC from inflamed pancreatic islets (Fig. 1) . Seven of eight NOD.SCID recipients that received 500,000 IIC from 11-wk-old NOD mice became diabetic by 36 days post-transfer. Cotransfer of 5 million CD4 ϩ splenocytes from 6-wk-old NOD mice significantly delayed the onset of diabetes FIGURE 1. CD4 ϩ CD25 ϩ splenocytes from prediabetic NOD mice delay diabetes transfer with IIC. Single-cell suspensions were prepared from inflamed pancreatic islets of 11-wk-old NOD mice. A total of 500,000 IIC were transferred into each NOD.SCID recipient either alone or together with 5 million CD4 ϩ splenocytes or 500,000 CD4 ϩ CD25 ϩ splenocytes or 5 million CD4 ϩ CD25 Ϫ splenocytes from 6-wk-old NOD mice. The onset of diabetes was monitored through urinary glucose measurements twice weekly. The data displayed are pooled from two independent experiments with similar results. 
2462
ϩ CD25 Ϫ splenocytes (Ͼ5 million) or a much larger number of recipient mice. However, this delaying effect would be modest in comparison with that seen with only 500,000 CD4 ϩ CD25 ϩ cells. As previously reported CD4 ϩ CD25 Ϫ peripheral lymphocytes depleted of recent thymic emigrants could protect against the development of diabetes in rats, suggesting that some regulatory activity is present in the CD4 ϩ CD25 Ϫ compartment (14) . Similarly, in the BDC2.5 transgenic system the abrupt onset of diabetes in BDC2. 5 Fig. 2B show that in contrast to the findings in vivo, both populations were equally anergic and suppressive in vitro.
It is possible that this assay is not sensitive enough to detect a mild contamination with nonregulatory T cells that nonetheless may be significant in vivo. In addition, the polyclonal stimulus neglects potential Ag-specific effects. However, an alternative explanation takes into account the specific nature of the CD62L molecule. CD62L (L-selectin) is an adhesion molecule that mediates lymphocyte extravasation through high endothelial venules (HEV) into lymph nodes and Peyer's patches as well as into chronically inflamed tissues through HEV-like structures (25) . We reasoned ϩ . However, CD4 ϩ CD25 ϩ CD62L ϩ and CD4 ϩ CD25 ϩ CD62L Ϫ cells are equally suppressive in vitro. A, IIC were isolated from pancreata of 11-wk-old NOD mice. A total of 500,000 cells were transferred into each NOD.SCID recipients either alone or together with 500,000 CD4 ϩ CD25 ϩ CD62L ϩ splenocytes, 500,000 CD4 ϩ CD25 ϩ CD62L ϩ , or 500,000 CD4 ϩ CD25 ϩ splenocytes from prediabetic NOD mice. The data displayed are pooled from two independent experiments with similar results. B,
Ϫ splenocytes from prediabetic NOD mice were incubated with anti-CD3 and anti-CD28 mAb-coated beads either alone or together with CD4 ϩ CD25 Ϫ splenocytes from the same mice. As a positive control, CD4 ϩ CD25 Ϫ splenocytes were incubated alone with beads. A total of 12,500 cells per well were used when cells were stimulated alone. In coincubation, decreasing numbers of CD4 ϩ CD25 ϩ CD62L ϩ or CD4 ϩ CD25 ϩ CD62L Ϫ cells were added to a constant (n ϭ 12,5000) number of CD4 ϩ CD25 Ϫ cells at the ratios indicated. The proliferation of cells was assessed by [ 3 H]thymidine incorporation. The results are representative of three independent experiments. that the functional difference between CD4 ϩ CD25 ϩ CD62L Ϫ and CD4 ϩ CD25 ϩ CD62L ϩ T cells in their capacity to delay diabetes transfer might be due to differential trafficking patterns of the two subpopulations.
cells express high levels of CCR7
Lymphocyte trafficking through the endothelium is a sequence of events involving adhesion molecules (such as CD62L), chemokine receptors, and integrins. Lymphoid chemokines are critical for trafficking into lymph nodes and within lymphoid compartments, whereas inflammatory chemokines attract lymphocytes into inflamed peripheral tissue (26) .
To test whether CD4
splenocytes differ in their chemotactic properties, we analyzed the expression of chemokine receptors in these subsets using RNase protection assays (Fig. 3A) . Different expression levels between the two subpopulations were apparent for CCR7 expression (higher in CD62L ϩ T cells) and CCR2, CCR4, and CXCR3 expression (higher in CD62L Ϫ T cells). These bands were quantified by densitometry (Fig. 3B) Fig. 4 ). Interestingly, a combinational code of CD62L and CCR7 expression is essential for entry into peripheral lymph nodes (27) . CD62L binding to peripheral node addressin on HEV initiates rolling (25) , which allows the engagement of CCR7 on lymphocytes to its ligand, SLC, on HEV. These steps are essential for the following integrin activation, firm adhesion, and transmigration (28) . Once in the lymph nodes, CCR7 expression directs the movement of T cells into the T cell area in response to SLC and ELC, where their interaction with APC and other T cells may take place (26) . In contrast, CCR2, CXCR3, and CCR4 have been found on activated/memory lymphocytes from a variety of noninflamed and inflamed tertiary tissues. Their chemokine ligands are expressed on APC and/or endothelial cells at tertiary sites (29 -31) .
How do these findings relate to the differential outcome in diabetes development following cotransfer of CD4
CD62
ϩ splenocytes and IIC into immune-incompetent NOD mice? The events following adoptive transfer of IIC into immune-incompetent NOD mice are complex. Islet-reactive lymphocytes are believed to be primed in the pancreatic lymph nodes by APC that present islet Ags (32) . Following activation, islet-reactive lymphocytes home to the pancreas and initiate ␤-cell destruction. We hypothesize that the specific adhesion molecule and chemokine receptor expression profile of the CD4 ϩ CD25 ϩ
CD62L
ϩ cells allows them to more efficiently enter the pancreatic lymph nodes where they can productively interact with and potentially inhibit the activation of IIC.
Our data are suggestive, but not conclusive. We have tried to follow the early migration of the transferred cell population using CFSE-labeled cells. However, the nature of the system (difficulties 
Ϫ ) splenocytes from prediabetic NOD mice were FACS sorted. RNA was prepared, and RNase protection assay was performed using the indicated chemokine probes. B, The polyacrylamide gel (shown in A) was scanned, and densitometry was performed. The values obtained for the chemokine receptors were normalized against GAPDH. The results are expressed as the mean Ϯ SD of values from two independent experiments. 
